(Total Views: 722)
Posted On: 12/04/2020 7:19:27 PM
Post# of 148949
“I think it is unusual to post an article about a foreign approval process that does not even mention CytoDyn. What is slightly weird about it is the fact that this article came out on December 2 and the CC PR came out on December 3.”
Each CC over the past 8 months has produced many, many unlikely scenarios, put together by shareholders from various pieces of information. To date, none of those scenarios has come to fruition. The most likely scenario has always been the answer and it will be the same in regards to CYDY posting the Phillippines article on their website: CYDY plans on filing for EUA in the Phillippines with the data from the S/C trial. Leronlimab is much more valuable as a drug for the S/C population then the M2M population, especially considering supply, so an EUA in the Phillippines for the M2M population will not happen first.
Each CC over the past 8 months has produced many, many unlikely scenarios, put together by shareholders from various pieces of information. To date, none of those scenarios has come to fruition. The most likely scenario has always been the answer and it will be the same in regards to CYDY posting the Phillippines article on their website: CYDY plans on filing for EUA in the Phillippines with the data from the S/C trial. Leronlimab is much more valuable as a drug for the S/C population then the M2M population, especially considering supply, so an EUA in the Phillippines for the M2M population will not happen first.
(4)
(0)Scroll down for more posts ▼
